AWAKEN HGH STUDY

J. Marcellus Mills, M.D. of the A. F. A. (Anti-Aging Foundation of America) clinically evaluated and assisted in a six-month study involving the administration of a polymer matrix oral spray Human Growth Hormone delivery system.  One hundred eighty-one healthy patients were screened and tested (99 females and 82 males).  IGF-1 testing is presently the standard accepted protocol for evaluating the level of human growth hormone in the blood.  Patients were pre-examined to determine a baseline IGF-1: 104.37 ng/mL in females (average 47) and 141.87ng/mL in males (average age 48).  No change in diet was advised.  Testing began with awakening (equalling approximately 200ng of HGH) and 2 sprays in the afternoon, plus 2 sprays in the evening immediately before retiring (totaling approximately 600ng of HGH per day, seven days a week).   

Thirty days after inception, testing showed that patient's IGF-1 levels were elevated 28% over baseline: 133.59ng/mL in females and 181.09 ng/mL in males.  After 60 days, IGF-1 levels were tested again and shown to be 61% over baselines: 168.04 ng/mL in females and 280.90 ng/mL in males.  At the end of the 6 month study, IGF-1 levels had increased over 98% over baseline in females(206.65ng/mL) and 112% over baseline in males(300.76ng/mL).  Cholesterol levels were also diminished in 94 patients by an average of 10.1% and triglyceride levels were also reduced by 28%.  Improvements were noted in mental stability, muscle accretion, weight reduction, energy level., libido, epidermis rejuvenation, and reacquired hair color and density.  In all 181 patients no adverse side effects were reported or observed.  The study suggests that the use of the 191 amino acid growth hormone molecule administered in a sublingual application is an effective method for encouraging and promoting the rejuvenation of cellular tissues.